肺康宁合剂治疗慢性阻塞性肺疾病肺动脉高压的临床研究

Clinical study of treatment with Feikangning Composition for chronic obstructive pulmonary diseases complicating pulmonary hypertension

目的研究肺康宁合剂治疗慢性阻塞性肺疾病肺动脉高压患者的临床疗效。方法将平均肺动脉压高于20 mmHg(1 mmHg=0.133 kPa)的慢性阻塞性肺疾病患者49例随机分成治疗组29例和对照组20例,对照组予常规方法治疗,治疗组则加服肺康宁合剂治疗,测定2组治疗前后平均肺动脉压及内皮素水平,并进行临床疗效指标的比较。结果2组患者经过2周治疗后,治疗组综合疗效及对氧分压的改善优于对照组(P均<0.05)。结论肺康宁合剂治疗慢性阻塞性肺疾病肺动脉高压发作期有较好的临床疗效,并能有效地降低肺动脉压,其作用机制可能与改善缺氧,改善血液流变学指标,影响D-二聚体、ET水平有关。

Objective It is to investigate the curative effect of Feikangning Composition on chronic obstructive pulmonary disease （COPD） complicating pulmonary hypertension. Methods 49 patients with COPD complicating pulmonary hypertension were divided into therapy group （29 patients） and control group （20 patients） randomly, all patients were treated by the routine method, and added Feikangning Composition in the therapy group. Mean pulmonary arterial pressure （MPAP）, endothelin （ET）, index of Blood rheology, D-dimer before and after treatment were measured and compared in the both groups. Results The total effective rate and the improvement of p（O2） in the therapy group were excelled significantly than that in the control group after treatment two weeks （ P 〈 0.05）. Concljusion Feikangning Composition has a favorable effect on treating COPD complicating pulmonary hypertension and can efficiently lower MPAP of patients, the mechanism of action possible relates to improvement of index of blood rheology and hypoxia, descensus of D- dimer and ET.